Stock AnalizRepligen Corp. RGEN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 1986 · data as of November 13, 2026
Repligen Corp. (RGEN) is a healthcare company listed in the US with a market value of about $10.7B. In the twelve months to September 30, 2026 it had revenue of $806M and net income of -$12M, a net margin of -1.5%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 100.5, 5-year revenue growth of 15% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $806M | $738M | $634M | $632M | $802M | $671M | $366M | $270M | $194M | $141M | $105M |
| Net income | -$12M | $49M | -$26M | $36M | $186M | $128M | $60M | $21M | $17M | $28M | $12M |
| Free cash flow | $107M | $94M | $150M | $78M | $87M | $52M | $40M | $49M | $22M | $12M | $3M |
| EPS (diluted) | $-0.21 | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 | $1.11 | $440.00 | $370.00 | $720.00 | $0.34 |
| Net margin | -1.5% | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | 16.4% | 7.9% | 8.6% | 20.1% | 11.2% |
| ROIC | — | 1.6% | -1.2% | 1.1% | 8.2% | 6.6% | 3.1% | 2.7% | 2.8% | 1.9% | 9.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $203.21, 21% above the current price; targets range from $175.00 to $235.00; the consensus rating is “Buy”; expected EPS is $2.07 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Repligen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Repligen pay a dividend?
Not currently.
Is Repligen a good stock to buy?
We do not give buy or sell advice. Repligen scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.